Drug intelligence / Profile preview

carboplatin + pemetrexed + tivantinib

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of carboplatin, pemetrexed, and tivantinib. Tivantinib is a selective non-ATP competitive oral inhibitor of the MET receptor, while carboplatin and pemetrexed are established chemotherapy agents. Preclinical data showed that MET inhibition blocks tumor cell growth and migration in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). This combination was investigated as a first-line treatment for patients with advanced non-squamous NSCLC or MPM.

Targets

TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on carboplatin + pemetrexed + tivantinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + pemetrexed + tivantinib.

Explore the full profile